Thyroid, Parathyroid, and Adrenal Research Charitable Foundation.
Long-Term Outcomes of Lateral Neck Dissection in Patients with Recurrent Thyroid Cancer
Long-Term Outcomes of Lateral Neck Dissection in Patients with Recurrent Thyroid Cancer
Long-Term Outcomes of Lateral Neck Dissection in Patients with Recurrent Thyroid Cancer
Dr Clayman reported the only long term analysis of patients with recurrent or persistent papillary thyroid cancer in the world. The results show that with expert surgery, patients can achieve control in their neck 98%. Thus, with expert surgery, even though patients may recur in their neck, their control and survival are not impacted when expert surgery is performed in their salvage.
The Genomic and Evolutionary Landscapes of Anaplastic Thyroid Cancer
Long-Term Outcomes of Lateral Neck Dissection in Patients with Recurrent Thyroid Cancer
Long-Term Outcomes of Lateral Neck Dissection in Patients with Recurrent Thyroid Cancer
In press Nature Genetics. This research is the first comprehensive analysis of the genetic errors in more favorable thyroid cancer such as papillary thyroid cancer and how these genetic events can further mount over time to evolve into one of the most aggressive cancers known to man. This international study was co-lead by Dr. Clayman with Dr. Paul Boutros of Canada.
Duration of high calcium establishes the severity of hyperparathyroidism.
Long-Term Outcomes of Lateral Neck Dissection in Patients with Recurrent Thyroid Cancer
Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer.
This landmark research for parathyroid patients was headed by Dr Boone. Presented at the 2017 meeting of the AAES and published in 2018, it examined more than 20,000 patients showing the height of calcium elevation does not correlate with disease severity--rather it is the duration of disease that matters. thyroid cancer
Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer.
Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer.
Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer.
In this research study, Dr Clayman examined whether elective removal of the lymph nodes of the side of the neck in patients with medullary thyroid cancer offers an advantage over just observation. It showed that when an expert ultrasound does not reveal any abnormal lymph nodes along the side of the neck, patients have the same likelihood of cure, neck disease control, and survival as those that underwent elective removal of the lymph nodes of the side of the neck.
Operative Findings in Lithium-Associated Primary Hyperparathyroidism
Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer.
Quality of Life Improvments in Patients with Primary Hyperparathyroidism
We are studying the largest series of patients with primary hyperparathyroidism as a result of long-term lithium therapy. Dr Boone presented at the 2018 Endocrine Society meeting on the clinical presentation and operative findings of LAH. These patients develop hyperparathyroidism due to a dramatically higher chance of multi-gland disease with an drug duration of 15 years required to develop.
Quality of Life Improvments in Patients with Primary Hyperparathyroidism
Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer.
Quality of Life Improvments in Patients with Primary Hyperparathyroidism
Using standardized quality of life questionnaires preoperatively and postoperatively, we have shown that pHPT is associated with dramatic declines in quality of life, which reverse in all areas after parathyroid surgery. Dr Boone presented these findings at the 2018 American Association of Clinical Endocrinologists annual meeting.
Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC
Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC
Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC
Dr Clayman analyzed >250 patients with recurrent or persistent papillary thyroid cancer debunking years of publications suggesting BRAF mutation portended decreased survival in patients with papillary thyroid cancer. Importantly, only TERT mutation effected survival in papillary thyroid cancer. New evidence suggests that TERT mutation is found in other more aggressive thyroid cancers including subsets of anaplastic thyroid cancer, one of the most lethal cancers of all. Journal Article
Improved Quality of Life After Parathyroid Surgery in Patients with Lithium-Associated PHPT
Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC
Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC
This is the largest study of Lithium-Associated Primary Hyperparathyroidism in the world and the first to look at quality of life. Presented by Dr Boone at 2018 American Association of Clinical Endocrinologists. She showed that these patients have a remarkable improvement in the quality of life and thus should be offered expert surgical care as soon as the calcium is elevated.
Normocalcemic Primary Hyperparathyroidism: Diagnosis and Surgical Findings.
Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC
Development and characterization of six new human papillary thyroid carcinoma cell lines
This uncommon form of hyperparathyroidism is being diagnosed more frequently as doctors screen for parathyroid disease, but the condition is still not well understood. With the largest series of normocalcemic patients in the world, we are evaluating the clinical presentation, operative findings, and outcomes for this unique subset of parathyroid patients.
Development and characterization of six new human papillary thyroid carcinoma cell lines
Development and characterization of six new human papillary thyroid carcinoma cell lines
Development and characterization of six new human papillary thyroid carcinoma cell lines
Dr Clayman presented six new papillary thyroid cancer cell lines which he developed in the laboratory over years of work. These cells lines remain his intellectual property and are the foundation for all laboratory research of papillary thyroid cancer. They are used globally for research secondary to the generosity of sharing these valuable resources. Journal Article
Detection of Thyroid Cancer Stem Cells in Papillary Thyroid Carcinoma
Development and characterization of six new human papillary thyroid carcinoma cell lines
Thyroid Ultrasound for Thyroid Cancer. Significant cancer is being missed.
Special populations of cells that can efficiently initiate tumor growth have been characterized, and this feature supports the cancer stem cell theory. These cancer stem cell populations have been identified with CD44 and POU5F1. Most cancer stem cells express high levels of CD44 and low levels of CD24. Journal Article
Thyroid Ultrasound for Thyroid Cancer. Significant cancer is being missed.
Development and characterization of six new human papillary thyroid carcinoma cell lines
Thyroid Ultrasound for Thyroid Cancer. Significant cancer is being missed.
This clinical research project was headed by Dr Clayman and presented at the 2018 meeting of the American Thyroid Assoc. The study showed that most thyroid ultrasound exams do not adequately examine lymph nodes which harbor thyroid cancer.
High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma
Papillary thyroid carcinoma (PTC), the most common thyroid malignancy, usually possesses BRAF mutation or rearranged in translation (RET)/PTC rearrangements. PTC usually possesses BRAF mutation or RET/PTC rearrangements. The mutation status of patients with recurrent PTC has never been characterized in a large population. Journal Article
Thyroid Cancer Information
You can help support real-world, meaningful Thyroid Cancer and Parathyroid/Adrenal Tumor Research!
Your support and contributions will enable us to meet the goals and mission of our non-profit 501(C)(3) charitable foundation.
